within Pharmacolibrary.Drugs.ATC.L;

model L01EA03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.00036166666666666666,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.4,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006666666666666667,
    Tlag           = 40.2,            
    Vdp             = 1.1,
    k12             = 46,
    k21             = 46
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Nilotinib is a second-generation oral tyrosine kinase inhibitor targeting BCR-ABL and is used primarily in the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (CML). It is currently approved and widely used in clinical practice for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from adult patients with chronic myeloid leukemia following oral administration under fasting conditions.</p><h4>References</h4><ol><li><p>Trent, J, &amp; Molimard, M (2011). Pharmacokinetics and pharmacodynamics of nilotinib in gastrointestinal stromal tumors. <i>Seminars in oncology</i> 38 Suppl 1 S28–S33. DOI:<a href=\"https://doi.org/10.1053/j.seminoncol.2011.01.014\">10.1053/j.seminoncol.2011.01.014</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21419933/\">https://pubmed.ncbi.nlm.nih.gov/21419933</a></p></li><li><p>Xia, B, et al., &amp; Lin, TH (2012). Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. <i>Biopharmaceutics &amp; drug disposition</i> 33(9) 536–549. DOI:<a href=\"https://doi.org/10.1002/bdd.1821\">10.1002/bdd.1821</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23097199/\">https://pubmed.ncbi.nlm.nih.gov/23097199</a></p></li><li><p>Yin, OQ, et al., &amp; Schran, H (2010). Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. <i>Journal of clinical pharmacology</i> 50(8) 960–967. DOI:<a href=\"https://doi.org/10.1177/0091270009346061\">10.1177/0091270009346061</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20498287/\">https://pubmed.ncbi.nlm.nih.gov/20498287</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EA03;
